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Polyclonal antibodies raised against a synthetic pcptide consisting of the last 19 amino acids at the end of the coiled-coil 
region of the heavy chains inhibited the actin-activated Mg2+-ATPase activity of myosin II and its ability to form fila- 
ments. Antibodies against a synthetic peptide corresponding to the 21 adjacent amino acids at the beginning of the non- 
helical tailpiece, which include the three regulatory phosphorylatable serines, had no effect on either activity. 
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1. INTRODUCTION 
Each of the two heavy chains of Acantharnoeba 
myosin II [l-3] consists of a globular head region 
of molecular mass about 90 kDa, which contains 
the actin- and ATP-binding sites [4], and an ex- 
tended a-helical tail of molecular mass about 
81 kDa, which joins with the tail of a second heavy 
chain to form a coiled-coil rod approx. 90 nm long 
[5]. An endogenous kinase phosphorylates three 
serine residues [6] that are located at positions 11, 
16 and 21 from the COOH-terminus [5,7] of each 
heavy chain within a 29-amino-acid residue non- 
helical tailpiece. Phosphorylation reversibly in- 
hibits actin-activated Mg’+-ATPase activity 
[6,8-101. 
Partial digestion of myosin II with cY-chymo- 
trypsin [7] releases a 66-amino-acid peptide (com- 
prising the last 37 amino acids of the helical region 
and the non-helical tailpiece) from the COOH- 
terminus of each heavy chain. Chymotrypsin- 
cleaved myosin II is unable to form bipolar 
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filaments and has no actin-activated Mg’+-ATPase 
activity, although it retains full Ca2+-ATPase 
activity and can associate into parallel dimers 
[11,12]. These, and other [5,11-151, data suggest 
that a small region at the COOH-terminus of the 
heavy chains is essential for the formation of 
bipolar filaments, that bipolar filaments are 
necessary for actin-activated Mg’+-ATPase activi- 
ty, and that phosphorylation regulates this en- 
zymatic activity by affecting filament conforma- 
tion. Kiehart and Pollard’s observations [ 16- 181 
that monoclonal antibodies, that were shown by 
electron microscopy to bind near the end of the 
tail, inhibit the actin-activated Mg’+-ATPase ac- 
tivity of myosin II and cause the filaments to 
depolymerize are consistent with these ideas. 
Now, we have raised polyclonal antibodies to 
two synthetic peptides with sequences corre- 
sponding to the very end of the helical region and 
to the adjacent beginning of the non-helical 
tailpiece of the myosin II heavy chain. These an- 
tibodies have provided sensitive site-specific pro- 
bes with which to investigate the roles of these two 
regions of the molecule in regulating filament 
assembly and actin-activated enzymatic activity of 
myosin II. 
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2. EXPERIMENTAL 1431 
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Acanthamoeba myosin II [19], dephosphorylated myosin II 
[8] and actin [20] were prepared as described. Peptides were 
synthesized on a Vega coupler 250 solid-phase peptide syn- 
thesizer using the standard Merrifield procedure [21,22]. Pep- 
tide purity was confirmed by reverse-phase HPLC, amino acid 
analysis and amino acid sequencing. 
Antibodies were raised in rabbits by injecting the peptides 
cross-linked to bovine serum albumin [23,24]. Antibodies were 
purified by ammonium sulfate precipitation, chromatography 
on DE52 (Whatman) to remove non-IgG components, and 
removal of anti-albumin antibodies by passage through an 
albumin-Sepharose CL-4B column, and concentrated by 
ultrafiltration. Rabbit polyclonal antibodies were also raised 
against native myosin II. Actin-activated Mg*+-ATPase and 
Ca*+-ATPase assays [8,9], protein determinations [25], 
polyacrylamide gel electrophoresis [26], and electroblotting [27] 
were performed by published procedures. 
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Fig.1. Amino acid sequence of the COOH-terminal 79 amino 
acids of the heavy chains of Acanfhamoeba myosin 11, residues 
1431-1509 [5,7]. The lines beneath the sequence identify the 
predominantly hydrophobic amino acids that occur at 
alternating intervals of 3 and 4 beginning at residue 847 and 
ending abruptly at residue 1479 [5]. The lines above the 
sequence identify the three serine residues whose 
phosphorylation inactivates the actin-activated Mg*‘-ATPase 
activity of native myosin Il. The space following Phe 1443 
indicates the site of cleavage by cu-chymotrypsin that removes 
the COOH-terminal 66 residues. The sequences corresponding 
to the synthesized peptides PI and P2 are shown in parentheses. 
3. RESULTS 
3.1. Peptides and antibodies 
The sequence of the COOH-terminal 79 amino 
acids of the heavy chains of Acanthamoeba 
myosin II and the locations of the sequences cor- 
responding to the two synthesized peptides are 
shown in fig. 1: peptide Pl corresponds to the first 
21 amino acids of the predicted non-helical 
tailpiece (including the 3 phosphorylatable 
serines), and peptide P2 corresponds to the im- 
mediately preceding 19 amino acids at the end of 
the long segment that defines the a-helical coiled 
coil region. The antibodies raised against Pl @Pl) 
and P2 (cyP2) had the expected specificities. Both 
reacted in immunoblots with intact myosin II 
heavy chain but not with the chymotrypsin-cleaved 
heavy chain, which lacks the COOH-terminal 66 
amino acids (fig.l), whereas antibodies raised 
against native myosin II (czMII) bound to both the 
intact and modified heavy chains (not shown). 
dephosphorylated myosin II is not surprising as 
this antibody was raised against an unphosphory- 
lated peptide. The same differential affinity of ~vP1 
was obtained with myosins denatured by heat or 
guanidine (not shown). This indicates that the 
slightly lower affinity of aP1 for phosphorylated 
myosin is due directly to the substitution of phos- 
phoserines for serines rather than to different con- 
formational states of this epitope in the phospho- 
rylated and dephosphorylated proteins. On the 
other hand, the differential binding of crP2 to the 
phosphorylated and dephosphorylated myosins 
was eliminated when the myosins were denatured. 
This suggests that phosphorylation of the non- 
helical tailpiece may cause a slight unfolding or in- 
crease in mobility of the adjacent helical, coiled- 
coil region which is the epitope for aP2. Results 
consistent with these conclusions were obtained in 
competition experiments using soluble monomeric 
and filamentous dephosphorylated and phospho- 
rylated myosin II (not shown). 
The antibody reactions were quantified by 
ELISA (fig.2). Each antibody had higher titer with 
the peptide against which it was raised than with 
myosin II (fig.2A,B), and neither reacted with the 
other peptide (not shown). Whereas aMI had 
identical titer against phosphorylated and dephos- 
phorylated myosin (fig.2A), cvP1 had a 2-fold 
higher titer against dephosphorylated than phos- 
phorylated myosin (fig.2B), and ~yP2 consistently 
showed a slightly higher titer (1.5fold) against 
phosphorylated than dephosphorylated myosin 
(fig.2C). The higher titer of ~yP1 with 
3.2. Effects of aP1 and cvP2 on the enzymatic 
activity of myosin II 
In the experiments described in fig.3, monomers 
of dephosphorylated myosin II were incubated 
with serial dilutions of auP1 and (up2 for 30 min 
and then assayed for actin-activated Mg’+-ATPase 
activity after dilution into the assay buffer. En- 
zymatic activity was strongly inhibited by CXP~ 
whereas aP1 had no effect. The inhibition was not 
the result of non-specific cross-linking of myosin 
molecules since monovalent Fab fragments of aP2 
also inhibited enzymatic activity (not shown). The 
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Fig.2. ELISA of antibodies against dephosphorylated and 
phosphorylated myosin II and synthetic peptides Pl and P2. 
100 al/well of 20 /g/ml dephosphorylated (0) or phosphory- 
lated (0) myosin II or synthetic peptides Pl or P2 (0) in 
20 mM phosphate (pH 7.3) and 120 mM NaCl were incubated 
at 37°C for 12 h in Immulon II microtiter plates (Dynatech, 
Alexandria, VA). Unbound antigen was removed by washing 
with 20 mM phosphate (pH 7.3) and 120 mM NaCl containing 
0.05% Tween 20 (Sigma). 100~1 of 4-fold serial dilutions of 
LuMII, purified aP1, or purified (up2 in the washing buffer were 
added to the wells and the plates were incubated for 1 h at 
37°C. The unbound antibody was washed off, and 100~1 of a 
standard dilution of horseradish peroxidase conjugated to goat 
anti-rabbit IgG antibody (Boehringer) added to each well. After 
incubation at 37°C for 1 h and washing, the bound antibody 
was visualized using o-phenylenediamine (Sigma) as a substrate. 
The color was quantified by absorbance at 492 nm using a 
Chromoscan EIA reader. 
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Fig.3. Effect of cvP1 and cup2 on actin-activated Mg’+-ATPase 
activity and filament formation of dephosphorylated myosin II. 
For Mg’+-ATPase assays, 10 pg dephosphorylated myosin II in 
a final volume of 25 pl was incubated with 4-fold serial 
dilutions of cvP1 or cvP2 in IO mM phosphate (pH 7.3) for 
30 min at room temperature. The myosin was diluted to a 
concentration of 40 yg/ml in the enzyme assay buffer in which 
the F-actin concentration was 50pg/ml. For filament 
formation assays, 30 pg dephosphorylated myosin II in a final 
volume of 75 pl was incubated with 4-fold serial dilutions of 
cvP1 or cvP2 in 10 mM phosphate (pH 7.3) for 30 min at room 
temperature. Samples were then diluted into Mg*+-ATPase 
assay conditions and duplicate samples were then either 
centrifuged at 30 lb/inch’ for 10 min in a Beckman airfuge or 
allowed to stand at room temperature. Aliquots (75 ~1) of the 
supernatant of each sample were carefully aspirated and 
analyzed by polyacrylamide gel electrophoresis together with 
equal aliquots of the samples that were not centrifuged. The 
gels were stained and destained, the protein-bound Coomassie 
blue was eluted with 1 ml of 25% pyridine in HzO, and its 
absorbance measured at 595 nm to estimate the percentage of 
myosin that remained soluble. 
non-physiological, unregulated Ca’+-ATPase ac- 
tivity of myosin II was not inhibited by either aP1 
or cup2 at the highest concentrations that could be 
tested (not shown). Neither aP1 nor aP2 inhibited 
the actin-activated Mg’+-ATPase activity when 
they were added to filaments of myosin II. 
Since only filamentous myosin II expresses 
actin-activated Mg’+-ATPase activity, we tested 
the abilities of cvP1 and LYP~ to block the formation 
of filaments which normally occurs when 
monomeric myosin II is diluted into the enzyme 
assay buffer (fig.3); aP1 had no detectable effect 
but aP2 inhibited filament formation. However, 
the concentration of ~uP2 necessary to prevent 50% 
of the myosin from forming filaments was about 
3-fold higher than that required to inhibit the 
actin-activated Mg’+-ATPase activity. In a control 
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experiment, the Fab fragment of aP2 also blocked 
formation of myosin II filaments (not shown). 
4. DISCUSSION 
Our data are consistent with the previous 
evidence that only filaments of myosin II express 
actin-activated Mg2+-ATPase activity [ 1 I, 141, and 
that antibodies that bind close to the carboxyl end 
of the heavy chain can inhibit both filament for- 
mation and actin-activated Mg2+-ATPase activity 
[ 16-181. The present data extend those earlier 
results by showing that antibodies to the 19 amino 
acids at the end of the a-helical coiled-coil region 
are inhibitory while antibodies to the immediately 
following 21 amino acids at the beginning of the 
non-helical tailpiece, which include the regulatory 
phosphorylatable serines, are without effect. The 
importance of the very end of the helical region for 
both filament formation and enzymatic activity 
suggests that phosphorylation of the regulatory 
serines in the non-helical tailpiece may inactivate 
myosin II by affecting the conformation of this 
neighboring helical region. Some support for this 
idea comes from the fact that phosphorylation of 
myosin II increases its affinity for aP2 whose 
epitope lies within that helical region. 
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